摘要
目的探讨氨磷汀联合吉西他滨与顺铂方案治疗晚期乳腺癌的临床效果。方法选取2014年5月~2016年6月石河子大学医学院第一附属医院收治的140例晚期乳腺癌患者作为研究对象,根据随机数字表法将其分为实验组与参照组,每组各70例。参照组患者给予吉西他滨与顺铂方案进行治疗,实验组患者在对照组的基础上加行氨磷汀治疗,比较两组患者的治疗总有效率、不良反应总发生率、生存时间及1、2年预期总生存率,并观察两组患者治疗前后的疼痛情况。结果实验组患者的治疗总有效率(71.43%)高于参照组(58.57%),差异有统计学意义(P<0.05);实验组患者的不良反应总发生率(14.29%)低于参照组(25.71%),差异有统计学意义(P<0.05);实验组患者的生存时间长于参照组,1、2年预期总生存率高于参照组,差异有统计学意义(P<0.05);治疗后,实验组患者的疼痛评分低于参照组,差异有统计学意义(P<0.05);两组患者治疗后的疼痛评分均低于治疗前,差异有统计学意义(P<0.05)。结论晚期乳腺癌患者采用氨磷汀联合吉西他滨与顺铂方案进行治疗,可以提高临床效果,降低不良反应总发生率,值得推广应用。
Objective To investigate the clinical effect of Amifostine combined with Gemcitabine and Cisplatin in the treatment of advanced breast cancer.Methods A total of 140 patients with advanced breast cancer treated in the First Affiliated Hospital,School of Medicine,Shihezi University from May 2014 to June 2016 were selected as the study subjects.They were divided into experimental group and reference group by random number table method,with 70 cases in each group.The control group was treated with Gemcitabine and Cisplatin,and the experimental group was treated with Amifostine.The total effective rate,the total incidence of adverse reactions,the survival time and the 1-year and 2-year expected survival rates of the two groups were compared,and the pain of the two groups before and after treatment was observed.Results The total effective rate of the experimental group(71.43%)was higher than that of the reference group(58.57%),and the difference was statistically significant(P<0.05).The total incidence of adverse reactions in the experimental group(14.29%)was lower than that in the reference group(25.71%),and the difference was statistically significant(P<0.05).The survival time of the experimental group was longer than that of the reference group,and the 1-year and 2-year expected overall survival rate was higher than that of the reference group,the differences were statistically significant(P<0.05).After treatment,the pain score of the experimental group was lower than that of the reference group,the difference was statistically significant(P<0.05).The pain scores of the two groups after treatment was lower than those before treatment,the differences were statistically significant(P<0.05).Conclusion For patients with advanced breast cancer,Amifostine combined with Gemcitabine and Cisplatin can improve the therapeutic effect and reduce the total incidence of adverse reactions,which is worthy of promotion and application.
作者
穆亚男
MU Ya-nan(Department of Pathology,Shihezi University School of Medicine,Xinjiang Uygur Autonomous Region,Shihezi 832003,China)
出处
《中国当代医药》
2020年第2期87-90,共4页
China Modern Medicine
关键词
氨磷汀
吉西他滨
顺铂
晚期乳腺癌
临床治疗效果
Amifostine
Gemcitabine
Cisplatin
Advanced breast cancer
Clinical treatment effect
